Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis

ClinicalTrials.gov ID: NCT07344558

Public ClinicalTrials.gov record NCT07344558. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Phase 1b Clinical Study of the Safety, Tolerability, and Pharmacokinetics of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

MKC-NI-002 is a Phase 1b, randomized, double-blind, placebo-controlled study of nintedanib inhalation powder (MNKD-201) in patients with Idiopathic Pulmonary Fibrosis (IPF). The trial consists of Multiple Ascending Doses (MAD) with the primary objective to evaluate safety, tolerability and pharmacokinetics (PK) of MNKD-201 compared to placebo in patients with IPF.

Study identification

NCT ID
NCT07344558
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Mannkind Corporation
Industry
Enrollment
27 participants

Conditions and interventions

Eligibility (public fields only)

Age range
40 Years to 85 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 22, 2025 (Actual)
Primary completion
Jun 17, 2026 (Actual)
Completion
Jun 17, 2026 (Actual)
Last update posted
Jul 22, 2026

2025 – 2026

United States locations

U.S. sites
9
U.S. states
5
U.S. cities
8
Facility City State ZIP Site status
VALDI Fresno California 93720 —
Palmtree Clinical Research Palm Springs California 92262 —
Innova Pharma Research Doral Florida 33172 —
New Life Medical Research Hialeah Florida 33012 —
New Access Research and Medical Services Miami Florida 33186 —
Southeastern Research Center Winston-Salem North Carolina 27103 —
Low Country Research Charleston South Carolina 29406 —
Metroplex Pulmomary & Sleep Center McKinney Texas 75069 —
Pulmonary Medicine Consultants McKinney Texas 75071 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07344558, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 22, 2026 · Synced Oct 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07344558 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →